The cardiac rhythm management market is "about as bad as it has ever been," according to an analyst with Gabelli & Co., due in part to headwinds from a federal probe and a negative journal article.
MASSDEVICE ON CALL — The 2012 list of the world’s most ethical companies included a handful of medical device makers and group purchasing organizations, according to the research-based Ethisphere Institute.
The 2.3% tax on revenues slated to go into effect next year for medical device makers could top $650 million for the med-tech companies covered by Moody’s Investor Services, according to a report by the ratings agency.
The tax will help slow EBIDTA growth rates for the med-tech sector to between 1% and 4% over the next year to 18 months, according to Moody’s, with organic growth rates of between 2% and 3% during that period.
A rating agency specializing in evaluating risky investments added Boston Scientific (NYSE:BSX) to its "Risk List," citing the ongoing fallout from its ill-starred Guidant buyout, its accounting and governance practices and how it pays its executives.
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
Shares of Becton, Dickinson & Co. (NYSE:BDX) continued their slide today after closing down yesterday following the release of the medical products giant’s fiscal 1st quarter results.
Investors, reacting to a lower forecast for the rest of the year and to a nearly 17% profit slide, sent shares down to $77.51 last night, a 3.8% decline. Shares were trading at $76.89 as of about 12:50 p.m. today, down 0.8%.
Venture capital funding of life science startups, including biotech and medical device enterprises, rose by 21% last year, according to PricewaterhouseCoopers.
VCs dropped $7.5 billion on 785 life sciences deals during the year, according to a PwC report, "Zigzagging Upward," compiled using data from the PricewaterhouseCoopers LLP/National Venture Capital Assn. MoneyTree Report and Thomson Reuters.
Updated February 1, 2012 at 5:30 p.m.
The $372 million buyout of Navilyst Medical by AngioDynamics (NSDQ:ANGO) is a reset button that will reinforce the combined operation for the future, AngioDynamics CEO Joe DeVivo told MassDevice this afternoon.
Simbionix USA Corp. acquired the Arthro VR arthroscopic training simulator line from Spain’s GMV for an undisclosed amount.
The deal broadens Simbionix’s footprint in the orthopedic training arena. The Arthro VR features a line of simulated procedures using fiberglass limb replicas, 3D images and haptic sensation.